• Home
  • Our Pipeline
  • About Us
  • Science
    • Active Immunotherapies
    • GlyMab®
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Scancell appoints Dr Jean-Michel Cosséry as Non-Executive Chairman of the Board

by admin | Feb 1, 2023 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Interim Results for the 6 months ended 31 October 2022

by admin | Jan 25, 2023 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Result of Annual General Meeting

by admin | Nov 23, 2022 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Scancell in-licenses Vaccitech technology to advance Modi-2 towards the clinic

by admin | Nov 7, 2022 | Latest News, Modi-2, Moditope, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

First patient dosed in the expansion phase of the monotherapy arms of ModiFY

by admin | Oct 31, 2022 | Latest News, Modi-1, Moditope, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

Preliminary Results for the year ended 30 April 2022

by admin | Oct 28, 2022 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!
« Older Entries
Next Entries »

Recent Posts

  • Scancell Receives FDA Fast Track Designation for iSCIB1+
  • Scancell announces CFO Transition
  • Edison Report – Redesigning immunity: The next frontier in immuno-oncology
  • Scancell Financial Year 2026 Interim Results
  • H126: solid iSCIB1+ data underpins planned progress

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy